Globally,about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection.A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samp...Globally,about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection.A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples.The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions.This phase Ⅰ trial (NCT00549900) assessed the safety,tolerability,and immunogenicity of the vaccine in Chinese.Thirty healthy Chinese females,aged 15 to 45 years with a median age of 29.5 years,received three doses of Cervarix in Months 0,1,and 6.Safety was assessed via recording solicited local and systemic symptoms within 7 days and unsolicited symptoms within 30 days after each vaccination.Serious adverse events,new onset of chronic diseases,and other medically significant conditions were recorded throughout this trial.As an exploratory objective,HPV-16/18 antibody titers were determined by enzyme-linked immunosorbent assay in serum samples collected in Months 0 and 7.Pain at the injection site was the most frequently reported local symptom.Two subjects reported medically significant adverse events.Both cases were assessed as unrelated to vaccination by the investigator.In Month 7,100% seroconversion was observed for both anti-HPV-16 and anti-HPV-18 with high geometric mean antibody titers.HPV-16/18 AS04-adjuvanted vaccine,evaluated for the first time in Chinese females,was generally well tolerated and immunogenic,as previously shown in global studies.展开更多
We have cloned the E6 gene of human papillomavirus type 18 into anexpression plasmid pBD2.One of the recombinant plasmids (named pDV11) wasidentified by DNA analysis and protein product analysis.It could express a new...We have cloned the E6 gene of human papillomavirus type 18 into anexpression plasmid pBD2.One of the recombinant plasmids (named pDV11) wasidentified by DNA analysis and protein product analysis.It could express a newprotein whose molecular weight correspods well with the expected one.Afterpurification,the expressed protein showed a positive result in countercurrentimmuno-electrophoresis with anti-β-gal serum and was proved to be the expectedβ-gal/E6 fusion protein.The physical map of pDV11 was also prepared.展开更多
文摘Globally,about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection.A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples.The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions.This phase Ⅰ trial (NCT00549900) assessed the safety,tolerability,and immunogenicity of the vaccine in Chinese.Thirty healthy Chinese females,aged 15 to 45 years with a median age of 29.5 years,received three doses of Cervarix in Months 0,1,and 6.Safety was assessed via recording solicited local and systemic symptoms within 7 days and unsolicited symptoms within 30 days after each vaccination.Serious adverse events,new onset of chronic diseases,and other medically significant conditions were recorded throughout this trial.As an exploratory objective,HPV-16/18 antibody titers were determined by enzyme-linked immunosorbent assay in serum samples collected in Months 0 and 7.Pain at the injection site was the most frequently reported local symptom.Two subjects reported medically significant adverse events.Both cases were assessed as unrelated to vaccination by the investigator.In Month 7,100% seroconversion was observed for both anti-HPV-16 and anti-HPV-18 with high geometric mean antibody titers.HPV-16/18 AS04-adjuvanted vaccine,evaluated for the first time in Chinese females,was generally well tolerated and immunogenic,as previously shown in global studies.
基金The project was supported by National Natural Science Foundation of China
文摘We have cloned the E6 gene of human papillomavirus type 18 into anexpression plasmid pBD2.One of the recombinant plasmids (named pDV11) wasidentified by DNA analysis and protein product analysis.It could express a newprotein whose molecular weight correspods well with the expected one.Afterpurification,the expressed protein showed a positive result in countercurrentimmuno-electrophoresis with anti-β-gal serum and was proved to be the expectedβ-gal/E6 fusion protein.The physical map of pDV11 was also prepared.
文摘目的探究人类乳头瘤病毒18(human papillomavirus 18,HPV18)在不同病理类型宫颈癌中微小核糖核酸(miRNA)表达差异。方法选取30例HPV18阳性宫颈腺癌患者为A组,30例HPV18阳性宫颈鳞癌患者为B组,15例宫颈正常者为C组。验证A组与B组的病灶组织差异表达miRNA,比较三组的差异表达miRNA及靶基因的表达情况,并比较A组中不同年龄、分期、分化程度及转移情况者的表达情况。结果A组与B组的差异表达miRNA为miR-34、miR-19,A组的miR-19及存活素(survivin)表达显著高于B组,miR-34及蛋白酪氨酸磷酸酶基因(phosphatase and tensin homolog deleted on chromosome ten,PTEN)表达显著低于B组,且A组与B组miR-19和survivin高于C组,miR-34和PTEN低于C组,差异有统计学意义(P<0.05),A组中不同年龄者的上述指标表达比较,差异无统计学意义(P>0.05),不同分期、分化程度及转移情况者的上述指标表达比较,差异有统计学意义(P<0.05)。结论miR-19、miR-34、survivin及PTEN在HPV18阳性在不同病理类型宫颈癌中的表达差异显著,且不同分期、分化程度及转移情况者的表达情况差异明显。
